Table 1. Comparison of baseline characteristics between ABMR and stable subjects.
| Characteristics | Stable group | ABMR group | P value |
|---|---|---|---|
| Case number | 131 | 68 | NS |
| Age (years, mean ± SD) | 37.55±1.24 | 38.92±2.01 | NS |
| Male (%) | 62.60 | 55.88 | NS |
| Number of HLA mismatches | 3.52±0.83 | 3.41±0.76 | NS |
| PRA (%) | 0.00 | 0.00 | - |
| Immunosuppressive protocol | NS | ||
| Pred + MMF + CsA | 63 | 26 | |
| Pred + MMF + TAC | 59 | 34 | |
| Pred + MMF + CsA + SIR | 5 | 6 | |
| Pred + MMF + TAC + SIR | 4 | 2 | |
| Type of ABMR* | |||
| Acute ABMR | - | 23 | |
| Chronic active ABMR | - | 45 | |
| Grade of morphologic tissue injury* | |||
| Grade I | - | 25 | |
| Grade II | - | 33 | |
| Grade III | - | 10 | |
| C4d Scroing by IF* | |||
| C4d1 | - | 5 | |
| C4d2 | - | 17 | |
| C4d3 | - | 46 | |
| Criculating DSAs (MFI, mean ± SD) | |||
| Class I | - | 1322.15 ± 545.82 | |
| Class II | - | 1185.22 ± 650.08 |
ABMR, antibody-mediated rejection; NS, not significant; SD, standard deviation; HLA, human lymphocyte antigen; PRA, panel reactive antibody; Pred, prednisone; MMF, Mycophenolate Mofetil; CsA, Cyclosporin A; TAC, tacrolimus; SIR, sirolimus.
*The classification of ABMR are in accordance with Banff 2007 criteria.